// App-Quantinova.ai

E087 : Reduced joint synovitis assessment versus the global EULAR OMERACT synovitis score (GLOESS) to predict the response to secukinumab in patients with active psoriatic arthritis and inadequate response to conventional disease-modifying anti-rheumatic drugs: exploratory results from the ULTIMATE trial

Researchers

Presenter

  • Philip G Conaghan

Principal Investigators

  • Maria-Antonietta D'Agostino

  • Maarten Boers

  • Esperanza Naredo

  • Peter Mandl

  • Philippe Carron

  • Marina Backhaus

  • Alejandra López-Rodríguez

  • Petra Hanova

  • Punit Goyanka

  • Braja G Sahoo

  • Corine Gaillez

  • Weibin Bao

Medical Centers

  • Department of Rheumatology and Joint and Bone Research Unit, Hospital Fundación Jiménez Díaz and Autónoma University, Madrid, Spain

  • Department of Epidemiology and Data Science,Amsterdam UMC,Amsterdam,Netherlands

  • Department of Internal Medicine – Rheumatology and Clinical Immunology, Park-Klinik Weißensee, Berlin, Germany

  • Department of Radiation Oncology, Catholic University of the Sacred Heart, Rome, Italy

  • Department of Exprerimental And Clinical Rheumatology, Institute of Rheumatology, Prague , Czech Republic

  • Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK

  • Department of Hematology, University Hospital Leuven, Leuven, Belgium

  • Division of Rheumatology, Medical University of Vienna, Vienna, Hungary

  • Hepatology and Dermatology, Novartis Pharma AG, Basel, Switzerland

  • PSOAPS Clinical and Research Psoriasis Center, Dermatológico Country, Guadalajara, Mexico

Locations

  • Spain

  • United States

  • United Kingdom

  • Netherlands

  • India

  • Belgium

  • Germany

  • Austria

  • Italy

  • Switzerland

  • Czech Republic

  • Mexico

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved